https://www.fortunebusinessinsights.com/antibiotics-market-104583

Antibiotics Market Expansion Driven by Rising
Surgical Procedures Globally
The antibiotics market plays a critical role in global healthcare by treating a wide range of bacterial
infections. This market includes drug classes such as penicillins, cephalosporins, macrolides, and
fluoroquinolones, which are used in hospitals, clinics, and outpatient care settings. Growth is driven by the
rising incidence of infectious diseases, increasing awareness about early treatment, and advancements in
drug formulations. Efforts to combat antibiotic resistance and the development of novel antibiotics are also
shaping the market’s future. As healthcare access expands, particularly in emerging economies, the demand
for effective and affordable antibiotics continues to rise.
According to Fortune Business Insights, the global antibiotics market was valued at USD 41.63 billion in
2024. The market is projected to grow from USD 43.17 billion in 2025 to USD 58.24 billion by 2032,
exhibiting a CAGR of 4.4% during the forecast period. In 2024, North America dominated the antibiotics
market with a market share of 45.14%.
Top Companies Steering the Market
 Pfizer Inc. (U.S.)
 Abbott (U.S.)
 GSK plc. (U.K.)
 Sandoz Group AG (Switzerland)
 Bayer AG (Germany)
 Bristol-Myers Squibb Company (U.S.)
 Merck & Co., Inc. (U.S.)
 Astellas Pharma Inc. (Japan)

Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.) (U.S.)
 AbbVie Inc. (U.S.)
Key Industry Development – October 2024
In October 2024, Iterum Therapeutics plc of Ireland received FDA approval for ORLYNVAH (sulopenem
etzadroxil with probenecid) to treat uncomplicated urinary tract infections (uUTIs). This new antibiotic
combination addresses the growing need for effective therapies amid rising resistance .
Market Drivers & Growth Catalysts